Amgen and UCB announced the resubmission of the Biologics License Application to the U.S. FDA for Evenity (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk for fracture.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00PR Newswirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngPR Newswire2018-07-13 01:00:322018-07-13 13:01:27Amgen, UCB Resubmit Biologics License Application For Evenity To U.S. FDA